v3.26.1
Note 8 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Convertible Series F Preferred Stock [Member]    
Antidilutive securities (in shares) [1] 46,783 52,512
Series F Preferred Warrants [Member]    
Antidilutive securities (in shares) [2] 8,097,347 2,784,921
Common Stock Warrants [Member]    
Antidilutive securities (in shares) 2,102,467 2,262,203
[1] Calculation assumes conversion of the stated value and accrued dividends of the Series F Preferred Stock into Common Stock at a conversion price of $3.77 per share as of March 31, 2026, and a conversion price of $11.17 as of March 31, 2025.
[2] Calculation assumes exercise of the Preferred Warrants for cash into Series F Preferred Stock and subsequent conversion of the Series F Preferred Stock into Common Stock at a conversion price of $3.77 as of March 31, 2026, and a conversion price of $11.17 as of March 31, 2025.